参考文献/References:
[1]Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on localregional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B18. J Clin Oncol, 1997, 15(7):2483-2493.
[2]Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol, 1998, 16(8):2672-2685.
[3]Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nineyear results from National Surgical Adjuvant Breast and Bowel Project B18. J Natl Cancer Inst Monogr, 2001, (30):96-102.
[4]Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B18 and B27. J Clin Oncol, 2008, 26(5):778-785.
[5]Mauriac L, Durand M, Avril A, et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol, 1991, 2(5):347-354.
[6]Scholl SM, Fourquet A, Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer, 1994, 30(5):645-652.
[7]Danforth DN Jr, Cowan K, Altemus R, et al. Preoperative FLAC/granulocytecolonystimulating factor chemotherapy for stage Ⅱ breast cancer: a prospective randomized trial. Ann Surg Oncol, 2003, 10(6):635-644.
[8]Gianni L, Baselga J, Eiermann W, et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res, 2005, 11(24 Pt 1):8715-8721.
[9]van Nes JG, Putter H, Julien JP, et al. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of followup; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat, 2009, 115(1):101-113.
[10]Colleoni M, Minchella I, Mazzarol G, et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol, 2000, 11(8):1057-1059.
[11]Colleoni M, Viale G, Zahrieh D, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res, 2004, 10(19):6622-6628.
[12]Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized doubleblind multicenter study. Ann Oncol, 2001, 12(11):1527-1532.
[13]Ellis MJ, Coop A, Singh B,et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB1 and/or ErbB2positive, estrogen receptorpositive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol, 2001, 19(18):3808-3816.
[14]Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter doubleblind randomized trial. J Clin Oncol, 2005, 23(22):5108-5116.
[15]Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptorpositive breast cancer: the PreOperative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer, 2006, 106(10):2095-2103.
[16]Mlineritsch B, Tausch C, Singer C, et al. Exemestane as primary systemic treatment for hormone receptor positive postmenopausal breast cancer patients: a phase Ⅱ trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG17). Breast Cancer Res Treat, 2008, 112(1):203-213.
[17]Barnadas A, Gil M, González S,et al. Exemestane as primary treatment of oestrogen receptorpositive breast cancer in postmenopausal women: a phase Ⅱ trial. Br J Cancer, 2009, 100(3):442-449.
[18]Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptorpositive breast cancer. Cancer, 2007, 110(2):244-254.
[19]Chen AM, MericBernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy. Cancer, 2005, 103(4):689-695.
[20]Huang EH, Strom EA, Perkins GH, et al. Comparison of risk of localregional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys, 2006, 66(2):352-357.
[21]Straver ME, Rutgers EJ, Rodenhuis S, et al. The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy. Ann Surg Oncol, 2010, 17(9):2411-2418.
[22]KrainickStrobel UE, Lichtenegger W, Wallwiener D.Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase Ⅱb/Ⅲ trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer, 2008, 8:62.
[23]Bhattacharyya M, Ryan D, Carpenter R, et al. Using MRI to plan breastconserving surgery following neoadjuvant chemotherapy for early breast cancer. Br J Cancer, 2008, 98(2):289-293.
[24]Straver ME, Loo CE, Rutgers EJ. MRImodel to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. Ann Surg, 2010, 251(4):701-707.
[25]Boughey JC, Peintinger F, MericBernstam F, et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg, 2006, 244(3):464-470.